

ABBOTT LABORATORIES  
Form 8-K  
April 16, 2013

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D. C. 20549

---

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

**April 16, 2013**

Date of Report (Date of earliest event reported)

**ABBOTT LABORATORIES**

(Exact name of registrant as specified in its charter)

---

**Illinois**  
(State or other Jurisdiction  
of Incorporation)

**1-2189**  
(Commission File Number)

**36-0698440**  
(IRS Employer  
Identification No.)

---

**100 Abbott Park Road**

Edgar Filing: ABBOTT LABORATORIES - Form 8-K

Abbott Park, Illinois 60064-6400

(Address of principal executive offices)(Zip Code)

Registrant's telephone number, including area code: **(847) 937-6100**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 2.02 Results of Operations and Financial Condition.**

On January 1, 2013, Abbott Laboratories ( Abbott ) completed the previously announced distribution of 100% of the outstanding common stock of AbbVie Inc. ( AbbVie ) to Abbott s shareholders. AbbVie is now an independent public company trading under the symbol ABBV on the New York Stock Exchange.

Furnished as Exhibit 99.1 is Abbott s unaudited non-GAAP financial information for 2012 reflecting the presentation of the AbbVie business as a discontinued operation and other adjustments to provide a historical baseline of Abbott s standalone operating results from continuing operations and excluding specified items. Abbott plans to evaluate its future results from continuing operations against this historical baseline. Exhibit 99.1 also provides a reconciliation of this non-GAAP information to Abbott s historical consolidated results in accordance with GAAP.

Abbott uses various non-GAAP financial measures including, among others: net earnings excluding specified items and diluted earnings per common share excluding specified items. These non-GAAP financial measures adjust for factors that are unusual or unpredictable, such as acquisition-related costs, asset impairments, losses on extinguishment of debt, costs related to the separation of AbbVie, litigation reserve adjustments, acquired in-process research and development, tax audit settlements, restructuring and integration costs, and cost reduction initiatives. These non-GAAP financial measures also exclude intangible amortization expense to provide greater visibility on the results of operations excluding these costs, similar to how Abbott s management internally assesses performance. Abbott s management believes the presentation of these non-GAAP financial measures provides useful information to investors regarding Abbott s results of operations as these non-GAAP financial measures allow investors to better evaluate ongoing business performance. Abbott, however, cautions investors to consider these non-GAAP financial measures in addition to, and not as a substitute for, financial measures prepared in accordance with GAAP.

The financial information is intended for informational purposes only and does not purport to project Abbott s financial performance or cost structure for any future period. The financial information should be read in conjunction with the audited consolidated financial statements and accompanying notes and Management s Discussion and Analysis of Financial Condition and Results of Operations included in Abbott s Form 10-K/A for the year ended December 31, 2012.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

<b>Exhibit No.</b>	<b>Exhibit</b>
99.1	Unaudited non-GAAP Financial Information for Abbott Laboratories

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ABBOTT LABORATORIES**

Date: April 16, 2013

By: /s/ Thomas C. Freyman  
Thomas C. Freyman  
Executive Vice President, Finance and  
Chief Financial Officer